This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?

GLP-1 medications will likely expand beyond their current uses for diabetes or weight loss, according to money managers at Tema

Previous post Macy’s to add two Arkhouse nominees to board as firm ends its proxy contest
Next post KPMG failed to stop cheating on training exams, hit with $25 million in fines